Funding Agency: National Institutes of Health (NIH) Title: Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) Application Deadline: June 5, 2022 (standard due dates; program ends in 2025)
The purpose of this FOA is to encourage grant applications to study novel microbial-based cancer therapy (including therapies for oral cancer), imaging detection, and diagnosis strategies to overcome the limitations of inadequate conventional cancer imaging and therapies. Solutions may utilize bacteria, archaebacteria, bacteriophages, and other microorganisms and their products (but not oncolytic viruses). Funding Agency: National Institutes of Health (NIH) Title: Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed) Application Deadline: May 30, 2022; May30, 2023; May 30,2024
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIBIB R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. This FOA seeks to support programs that include innovative approaches to enhance biomedical engineering design education to ensure a future workforce that can meet the nations needs in biomedical research and healthcare technologies. Funding Agency: National Institutes of Health (NIH) Title: BRAIN Initiative Connectivity across Scales (BRAIN CONNECTS): Specialized Projects for Scalable Technologies (U01 Clinical Trial Not Allowed) Application Deadline: July 13, 2022; June 13, 2023; June 13, 2024
This Funding Opportunity Announcement (FOA) supports Specialized Projects to develop current or emerging technologies to generate comprehensive atlases of brain connectivity, with an emphasis on human, non-human primate (NHP), and mouse. Projects validating approaches using other species are also permitted if well justified. Applications may address any aspects of the data collection, analysis, and dissemination pipelines, to enable faster and more cost-effective generation and interpretation of brain-wide wiring diagrams. Projects will offer distinct capabilities and competencies aimed at developing and optimizing current technologies or entirely new and potentially risky approaches. Funding Agency: National Institutes of Health (NIH) Title: Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional) Application Deadline: June 22, 2022 (standard due dates; program ends in 2025)
The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies. Funding Agency: National Institutes of Health (NIH) Title: Partnerships for Rapid Diagnostics and Phenotypic Antibacterial Susceptibility Testing for Bacteremia or Hospital Acquired Pneumonia (R01 Clinical Trial Not Allowed) Application Deadline: June 01, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for projects focused on development and/or production of medical diagnostics that permit rapid differential species identification, and corresponding phenotypic antibacterial susceptibility profiles for bacteremia or hospital acquired pneumonia. The primary goal of such diagnostics is to facilitate antibacterial stewardship, thereby reducing selective pressure and improving patient outcomes. Funding Agency: National Institutes of Health (NIH) Title: Screening for Cognitive Impairment: Decision-Making (U24 Clinical Trial Optional) Application Deadline: July 11, 2022
This Funding Opportunity Announcement (FOA) invites research to develop, validate, and disseminate measurement tools that could be used to screen for deficits related to decision-making, planning, and other important higher order functional outcomes in older adults. In particular, we are interested in instruments that can track changes in decision-making capacity that could be useful in the context of future screening for cognitive impairment and the development of interventions targeting functional outcomes in persons living with cognitive impairment and/or quality of life outcomes in their care partners/caregivers. The goal of the FOA is to support a research network whose goals would be to review and assess the dimensions of higher cognitive abilities and functional capacities already believed to support higher order planning and decision-making, to develop valid and reliable measures of those abilities, and to provide support for pilot efforts during the instrument development and validation in a racially, ethnically, geographically, and diagnostically diverse set of participants as well as a set of enduring resources including the measurement instruments, documentation, and normative data that will enable other, future projects to incorporate the new measurements into studies.
|